HomeMarket NewsLeerink Predicts Structure Therapeutics Stock as "Undervalued" in Growing Oral GLP-1 Diabetes...

Leerink Predicts Structure Therapeutics Stock as “Undervalued” in Growing Oral GLP-1 Diabetes Drug Market

Actionable Trade Ideas

always free

Weight loss pills. Obesity treatment. Overweight problems.

Alexey Krukovsky

Overview:

Leerink, an investment bank specializing in healthcare, has stated that it believes Structure Therapeutics (NASDAQ:GPCR) is currently β€œsignificantly undervalued.” Leerink observes an β€œextraordinary” total addressable market for oral GLP-1 diabetes drugs, presenting a lucrative opportunity for Structure Therapeutics. The investment bank is particularly optimistic about the company’s GLP-1 drug candidate, GSBR-1290, following the release of Phase 1 data. Leerink believes this drug could be a strong competitor to Eli Lilly’s (LLY) GLP-1 oral drug candidate, forglipron. Furthermore, Leerink predicts the global peak potential sales for orally administered incretin drugs to be between $50 billion and $75 billion.

Price Target:

Based on their analysis, Leerink has raised the price target for Structure Therapeutics stock from $46 to $97.

Market Reaction:

As a result of the positive Phase 1 data release, Structure Therapeutics shares experienced a sharp increase in value. The company, which went public in February, is uniquely positioned to capitalize on the growing demand for oral GLP-1 diabetes drugs.

More on Structure Therapeutics

Swing Trading Ideas and Market Commentary

Need some new swing ideas? Get free weekly swing ideas and market commentary from Jonathan Bernstein here: Swing Trading.

Explore More

Weekly In-Depth Market Analysis and Actionable Trade Ideas

Get institutional-level analysis and trade ideas to take your trading to the next level, sign up for free and become apart of the community.